
A Silicon Valley startup named Preventive is exploring the use of gene editing technology to potentially create genetically engineered babies. Backed by high-profile investors such as Sam Altman of OpenAI and Brian Armstrong of Coinbase, the company focuses on using this technology to eliminate hereditary diseases by editing human embryos before birth. However, this research has sparked significant ethical concerns, as such practices are currently illegal in the United States and banned in many other countries.
Founded by gene-editing scientist Lucas Harrington, Preventive has raised $30 million to develop its innovative approach. The company aims to demonstrate that gene editing can be done safely and transparently, with plans to conduct further studies on how mRNA vaccines could be combined with cancer treatments. Despite skepticism surrounding mRNA technology, Harrington insists that their research is focused on preclinical studies and is not preparing to implant edited embryos yet.
The implications of Preventive’s work could reshape discussions around genetic engineering and public health. While the company is committed to transparency and following ethical guidelines, experts warn of the risks associated with gene editing. Past controversies, such as the case of the Chinese scientist who created the first gene-edited babies, highlight the importance of responsible practices in this rapidly evolving field.

